Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Halozyme Therapeutics, Inc. - Common Stock (NQ:HALO)

79.44 +2.52 (+3.28%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 13, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	1,735,501
Open	77.83
Bid (Size)	77.68 (100)
Ask (Size)	80.00 (100)
Prev. Close	76.92
Today's Range	77.55 - 81.19
52wk Range	47.50 - 82.22
Shares Outstanding	142,334,900
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Acadia Healthcare, Hims & Hers Health, RadNet, Halozyme Therapeutics, and Privia Health Shares Are Soaring, What You Need To Know

Today 15:50 EST

A number of stocks jumped in the afternoon session after a softer-than-expected inflation report fueled hopes for interest rate cuts by the Federal Reserve. The January Consumer Price Index (CPI), a...

Via StockStory

3 Small-Cap Stocks with Solid Fundamentals

February 08, 2026

In today’s market, large companies dominate the landscape and grow their leads by acquiring smaller competitors - a trend that will accelerate with the Trump administration. However, some lesser-known...

Via StockStory

Performance

YTD	+13.0%	+13.0%
1 Month	+10.8%	+10.8%
3 Month	+11.6%	+11.6%
6 Month	+21.2%	+21.2%
1 Year	+36.7%	+36.7%

More News

3 Growth Stocks Set to Flourish

February 01, 2026

Via StockStory

Halozyme Therapeutics Inc (NASDAQ:HALO) Presents a Compelling Growth and Technical Setup ↗

January 29, 2026

Via Chartmill

Halozyme Therapeutics Inc (NASDAQ:HALO) Passes Minervini Trend Template and High Growth Momentum Screen ↗

January 17, 2026

Via Chartmill

Halozyme Therapeutics Inc (NASDAQ:HALO) Presents a High-Growth Momentum and Technical Breakout Opportunity ↗

January 13, 2026

Via Chartmill

A Look Back at Therapeutics Stocks’ Q3 Earnings: United Therapeutics (NASDAQ:UTHR) Vs The Rest Of The Pack

January 29, 2026

Via StockStory

Q3 Earnings Highs And Lows: AbbVie (NYSE:ABBV) Vs The Rest Of The Therapeutics Stocks

January 28, 2026

Via StockStory

HALO Stock Edges Up 3% On Upbeat Multi-Year Revenue Guidance, Surf Bio Acquisition ↗

January 28, 2026

Via Stocktwits

Therapeutics Stocks Q3 Highlights: United Therapeutics (NASDAQ:UTHR)

January 27, 2026

Via StockStory

Halozyme Therapeutics Inc (NASDAQ:HALO) Presents a Compelling Growth at a Reasonable Price (GARP) Case ↗

January 06, 2026

Via Chartmill

HALOZYME THERAPEUTICS INC (NASDAQ:HALO) Presents a Compelling Value Investment Case ↗

December 31, 2025

Via Chartmill

Q3 Rundown: Amgen (NASDAQ:AMGN) Vs Other Therapeutics Stocks

January 25, 2026

Via StockStory

2 Under-the-Radar Biotech Stocks Set to Boom in 2026 ↗

January 24, 2026

Via The Motley Fool

Reflecting On Therapeutics Stocks’ Q3 Earnings: Vertex Pharmaceuticals (NASDAQ:VRTX)

January 21, 2026

Via StockStory

Unpacking Q3 Earnings: Vertex Pharmaceuticals (NASDAQ:VRTX) In The Context Of Other Therapeutics Stocks

January 19, 2026

Via StockStory

Halozyme Therapeutics: A 6.3 Rating and a Future Full of Uncertainty ↗

January 19, 2026

Via The Motley Fool

Q3 Therapeutics Earnings: Halozyme Therapeutics (NASDAQ:HALO) Earns Top Marks

January 18, 2026

Via StockStory

1 Surging Stock Worth Investigating and 2 We Brush Off

January 11, 2026

Via StockStory

Halozyme Therapeutics (HALO): Buy, Sell, or Hold Post Q3 Earnings?

January 07, 2026

Via StockStory

Q3 Earnings Outperformers: Novavax (NASDAQ:NVAX) And The Rest Of The Therapeutics Stocks

January 04, 2026

Via StockStory

Halozyme Therapeutics (NASDAQ:HALO) Reports Bullish Q3 CY2025

January 01, 2026

Via StockStory

Halozyme Therapeutics (NASDAQ:HALO): A Prime GARP Stock with Strong Growth and Value ↗

December 13, 2025

Via Chartmill

The Healthcare Sector Is Surging. Here's 1 Stock Every Investor Should Have on Their Radar. ↗

December 06, 2025

Via The Motley Fool

Halozyme Therapeutics Inc (NASDAQ:HALO) Presents a Compelling Case for Value Investors ↗

November 24, 2025

Via Chartmill

Frequently Asked Questions

Is Halozyme Therapeutics, Inc. - Common Stock publicly traded?

Yes, Halozyme Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does Halozyme Therapeutics, Inc. - Common Stock trade on?

Halozyme Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Halozyme Therapeutics, Inc. - Common Stock?

The ticker symbol for Halozyme Therapeutics, Inc. - Common Stock is HALO on the Nasdaq Stock Market

What is the current price of Halozyme Therapeutics, Inc. - Common Stock?

The current price of Halozyme Therapeutics, Inc. - Common Stock is 79.44

When was Halozyme Therapeutics, Inc. - Common Stock last traded?

The last trade of Halozyme Therapeutics, Inc. - Common Stock was at 02/13/26 04:00 PM ET

What is the market capitalization of Halozyme Therapeutics, Inc. - Common Stock?

The market capitalization of Halozyme Therapeutics, Inc. - Common Stock is 11.31B

How many shares of Halozyme Therapeutics, Inc. - Common Stock are outstanding?

Halozyme Therapeutics, Inc. - Common Stock has 11B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.